On 8th October, Huawei has obtained medical equipment manufacturing license and get an official from Guangdong Medical Device Registrant System. Now, the company is ready to bring more technologies to the medical industry.
According to the information, under the administration of Goertek Co., Ltd. and Weifang Jingwei High-Tech Electronic Technology Co., Ltd., Huawei has got permission for its new ECG smartwatch whose registration number is Guangdong Machinery Zhuzhun 20202071705.
Huawei’s Preparation for Future Medical Technology:
Using the leading intelligent layer approach, big data, and artificial intelligence technologies, the company wants to bring devices that are able to carry out real-time medical diagnoses. Besides, the above-mention ECG smartwatch, three more Huawei medical devices are listed to get the official approval. It includes-
- ECG blood pressure recorder (MLY-B10, MLY-B11)
- ECG analysis system (ECG-1)
- Arrhythmia analysis system (PPG-1)
Moving ahead, Huawei Consumer Business Mobile Phone Product Line President- He Gang previously confirmed that a Huawei smartwatch passed the medical device registration test and the registered clinics are started to take its trials.
In the future, this smartwatch will be able to measure blood pressure on the wrist. Meanwhile, it’s likely to be launched by the second half of this year, he informed. In addition, the company also opened the recruitment of blood pressure test subjects through its membership app with wrist circumference (larger than 200mm) and BP (above that 140mm Hg).
At present, the company is reported to develop the blood pressure measuring wearable accessory with high-precision native technologies. Simultaneously, it’s also conducting in-depth research on hypertension management incorporation with a local medical institution.
Huawei’s Current Activity in Medical Field:
As per the official data, the company’s medical equipment and technology is serving in about 3,000 health organizations at present. Furthermore, the company accelerates its speed in wireless network solution research to bring more reliable and comprehensive equipment for the medical industry.
Huawei opens new store in Saudi Arabia
On January 31, 2023, Huawei opened its new store at Jeddah Park in Saudi Arabia, as this counts as the second Experience store in the country with an opportunity for customers to get their favorite Huawei device.
Last year, Huawei launched its largest overseas flagship store in Saudi Arabia’s Riyadh, which expands over 2000 square meters with a minimalist design and provides a full-scenario experience to consumers.
Compared to that, the new Huawei store is expanding to 600 square meters and offers customers the to experience various technologies. These include devices such as smartphones, tablets, notebooks, wearables, and more.
According to the information, Huawei is also running offers and massive discounts for people who’ll visit the store from January 31 to February 4th, 2023.
Eric Yang, chairman and CEO of Huawei Tech Investment Saudi Arabia, said the new store in Jeddah reflects Huawei’s willingness to expand its business in the kingdom as well as its continued commitment to this strategic market.
Huawei will build first digital robot for pharmaceutical industry
Huawei will build the industry’s first digital robot with China’s National Pharmaceutical Group, Sinopharm for the pharmaceutical industry. This is a brand new progress made by the Chinese tech maker to advance its growth in digital robot technologies.
In 2019, Sinopharm began to explore digital robot technology. Several subsidiaries have implemented more than 200 business processes. There are problems such as scattered business scenarios, the inability to share robot resources, and inconsistent business processes. In order to solve some problems in the early testing, open up resource sharing, unify and optimize business processes, and realize the digitalization of deep integration of operations and business.
In 2022, Sinopharm joined hands with Huawei’s digital robot team and Huawei partners. This partnership focuses on key points such as customers, data, and business elements, sorted out the business process, and planned and built the first digital robot competence center platform in the domestic pharmaceutical industry.
Relying on the large-scale application capabilities of Huawei’s WeAutomate digital robots and mature product capabilities, Sinopharm has built a digital robot capability center platform that can meet the automation application needs of thousands of subsidiaries of the group.
After the launch, all subsidiaries of Sinopharm Holdings can share common tech in business processes, and share digital robot resources in a unified and intensive manner. In addition, the Sinopharm Digital Robotics Competence Center can fully support the group’s common situations and the personalized scenarios of the branch companies.
The common scene process is uniformly constructed by the headquarters and can be used by all branch companies. On the other hand, the custom scene process is customized and shared by the branch companies.
In the future, Huawei’s WeAutomate digital robot will continue to provide technological advantages and help Sinopharm to promote more general scenarios of digital robots to all sub-companies. On the basis of realizing the sharing of digital robot resources, it will simultaneously leverage the innovation capabilities of branch companies to meet business needs.
The process of implementing Huawei’s digital robots is also a process of normalizing and standardizing the general scenarios of branch companies, which promotes the optimization and unification of Sinopharm’s business processes. After the launch of the Sinopharm Digital Robotics Competence Center, the efficiency of the online robot business scenarios can be increased by up to 25 times, and the average efficiency can be increased by more than 10 times, effectively releasing digital momentum.
Sinopharm Holdings Co., Ltd. was established in Shanghai in January 2003 and listed in Hong Kong in September 2009. It includes two A-share listed companies, Sinopharm Group Pharmaceutical Co., Ltd. and Sinopharm Accord Pharmaceutical Co., Ltd., with a total of more than a thousand subsidiaries.
Now it has become a leading distributor and retailer of pharmaceuticals, healthcare products, and medical devices in China, as well as a leading supply chain service provider. Sinopharm ranks 22nd among Fortune China’s Top 500 in 2021.
Huawei Kirin and HarmonyOS appears in Chinese study syllabus
According to the inputs coming from Weibo, Huawei Kirin, HarmonyOS operating system and other self-developed Huawei technologies appeared in the study test syllabus question book.
A picture shared online shows questions that have carried out an inventory of the product names of China’s most influential technology companies. And said that these product names are very distinctive, including the mobile chipset “Kirin”, the operating system “HarmonyOS”, the server chip “Kunpeng” and more.
The latest appearance of these popular technologies is the result of the people behind the development that put countless hours to bring them into reality.